Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms

Modern Pathology

Volumn 19, Issue 12, 2006, Pages 1555-1562

  Jaye, David L ^a   Geigerman, Cissy M ^a   Herling, Marco ^b   Eastburn, Karen ^a   Waller, Edmund K ^a   Jones, Dan ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Blastic NK cell lymphoma; CD303; Plasmacytoid dendritic cell; Terminal deoxynucleotidyl transferase

Indexed keywords

ANTIBODY; BLOOD DENDRITIC CELL ANTIGEN 2; CD4 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; CELL SURFACE MARKER; DNA NUCLEOTIDYLEXOTRANSFERASE; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BLAST CELL; CANCER SURVIVAL; CD4 CD56 HEMATODERMIC NEOPLASM; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOPATHOLOGY; DENDRITIC CELL; FOLLOW UP; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; LEUKEMIA; LYMPHOMA; NATURAL KILLER CELL; NORMAL HUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SKIN TUMOR; T LYMPHOCYTE; TISSUE FIXATION;

ANTIGENS, CD4; ANTIGENS, CD56; ANTIGENS, NEOPLASM; DENDRITIC CELLS; DNA NUCLEOTIDYLEXOTRANSFERASE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; KILLER CELLS, NATURAL; LECTINS, C-TYPE; LYMPHOMA, NON-HODGKIN; MEMBRANE GLYCOPROTEINS; PLASMA CELLS; RECEPTORS, IMMUNOLOGIC; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33751236769     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800679     Document Type: Article

References (34)

1. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol 2005;123:662-675.
2. Petrella T, Meijer CJ, Dalac S, et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol 2004;122:307-313.
3. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785.
4. DiGiuseppe JA, Louie DC, Williams JE, et al. Blastic natural killer cell leukemia/lymphoma: a clinicopathologic study. Am J Surg Pathol 1997;21:1223-1230.
5. Chan JKC, Jaffe ES, Ralfkiaer E. Blastic NK-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Haemotopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001, pp. 214-215.
6. Suzuki R, Nakamura S, Suzumiya J, et al. Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. Cancer 2005;104:1022-1031.
7. Reichard KK, Burks EJ, Foucar MK, et al. CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol 2005;29:1274-1283.
8. Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002;99:1556-1563.
9. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001;97:3210-3217.
10. Chaperot L, Perrot I, Jacob MC, et al. Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol 2004;34:418-426.
11. Herling M, Teitell MA, Shen RR, et al. TCL1 expression in plasmacytoid dendritic cells (DC2 s) and the related CD4+ CD56+ blastic tumors of skin. Blood 2003;101:5007-5009.
12. Petrella T, Comeau MR, Maynadie M, et al. 'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002;26:852-862.
13. Comeau MR, Van der Vuurst de Vries AR, Maliszewski CR, et al. CD123bright plasmacytoid predendritic cells: progenitors undergoing cell fate conversion? J Immunol 2002;169:75-83.
14. Maeda T, Murata K, Fukushima T, et al. A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma. Int J Hematol 2005;81:148-154.
15. Khoury JD, Medeiros LJ, Manning JT, et al. CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer 2002;94:2401-2408.
16. Karube K, Ohshima K, Tsuchiya T, et al. Non-B, non-T neoplasms with lymphoblast morphology: further clarification and classification. Am J Surg Pathol 2003;27:1366-1374.
17. Bekkenk MW, Jansen PM, Meijer CJ, et al. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004;15:1097-1108.
18. Massone C, Chott A, Metze D, et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol 2004;28:719-735.
19. Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000;165:6037-6046.
20. Dzionek A, Sohma Y, Nagafune J, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 2001;194:1823-1834.
21. Anargyrou K, Paterakis G, Boutsis D, et al. An unusual case of CD4+ CD7+ CD56+ acute leukemia with overlapping features of type 2 dendritic cell (DC2) and myeloid/NK cell precursor acute leukemia. Eur J Haematol 2003;71:294-298.
22. Bueno C, Almeida J, Lucio P, et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica 2004;89:58-69.
23. Jacob MC, Chaperot L, Mossuz P, et al. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica 2003;88:941-955.
24. Fujita N, Jaye DL, Kajita M, et al. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003;113:207-219.
25. Jaye DL, Geigerman CM, Fuller RE, et al. Direct fluorochrome labeling of phage display library clones for studying binding specificities: applications in flow cytometry and fluorescence microscopy. J Immunol Methods 2004;295:119-127.
26. Waller EK, Rosenthal H, Jones TW, et al. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 2001;97:2948-2956.
27. Fujita N, Jaye DL, Geigerman C, et al. MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 2004;119:75-86.
28. Jaye DL, Nolte FS, Mazzucchelli L, et al. Use of real-time polymerase chain reaction to identify cell- and tissue-type-selective peptides by phage display. Am J Pathol 2003;162:1419-1429.
29. Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999;5:919-923.
30. Summers KL, Hock BD, McKenzie JL, et al. Phenotypic characterization of five dendritic cell subsets in human tonsils. Am J Pathol 2001;159:285-295.
31. Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999;5:919-923.
32. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306.
33. Urosevic M, Conrad C, Kamarashev J, et al. CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. Hum Pathol 2005;36:1020-1024.
34. Dzionek A, Inagaki Y, Okawa K, et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol 2002;63:1133-1148.